These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Pansclerotic morphea with a rapidly fatal outcome in an 11-year-old girl]. Hardy J; Audouin-Pajot C; Abid A; Chiotasso D; Coustets B; Suc A; Timsit P; Mouthon L; Mazereeuw-Hautier J Ann Dermatol Venereol; 2016 Dec; 143(12):836-840. PubMed ID: 27496274 [TBL] [Abstract][Full Text] [Related]
5. Pansclerotic morphea: A male child with hemiatrophy of lower limb. Dasgupta MK; Patra C; Sarkar S; Das S Indian Dermatol Online J; 2014 Apr; 5(2):170-2. PubMed ID: 24860754 [TBL] [Abstract][Full Text] [Related]
6. Pansclerotic morphea treated with UVA: a case report. Yildirim M; Baysal V; Aridogan BC; Kesici D; Erturan I J Dermatol; 2003 Aug; 30(8):625-7. PubMed ID: 12928533 [TBL] [Abstract][Full Text] [Related]
7. Hyaluronidase as a Successful Treatment Modality for Scleroderma-Induced Microstomia. Chopra D; Brehm JE; Morrison B Dermatol Surg; 2022 Sep; 48(9):1014-1015. PubMed ID: 35834642 [No Abstract] [Full Text] [Related]
8. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin]. Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902 [TBL] [Abstract][Full Text] [Related]
9. Coexistence of morphea and systemic sclerosis. Soma Y; Tamaki T; Kikuchi K; Abe M; Igarashi A; Takehara K; Ishibashi Y Dermatology; 1993; 186(2):103-5. PubMed ID: 8428037 [TBL] [Abstract][Full Text] [Related]
10. Squamous cell carcinoma in pansclerotic morphea of childhood. Wollina U; Buslau M; Weyers W Pediatr Dermatol; 2002; 19(2):151-4. PubMed ID: 11994182 [TBL] [Abstract][Full Text] [Related]
12. Disabling pansclerotic morphea of childhood with extracutaneous manifestations. Kura MM; Jindal SR Indian J Dermatol; 2013 Mar; 58(2):159. PubMed ID: 23716826 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathological study of 81 cases of localized and systemic scleroderma. Succaria F; Kurban M; Kibbi AG; Abbas O J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):e191-6. PubMed ID: 22620486 [TBL] [Abstract][Full Text] [Related]
14. Update on the classification and treatment of localized scleroderma. Bielsa Marsol I Actas Dermosifiliogr; 2013 Oct; 104(8):654-66. PubMed ID: 23948159 [TBL] [Abstract][Full Text] [Related]
15. Nodular morphea (NM): report of a case of concurrent NM and morphea profunda associated with limited type systemic sclerosis, and overview and definition for NM. Ohata C; Yasunaga M; Tsuruta D; Ishii N; Hamada T; Dainichi T; Karashima T; Nakama T; Hashimoto T Eur J Dermatol; 2013; 23(1):87-93. PubMed ID: 23400240 [TBL] [Abstract][Full Text] [Related]
18. Disabling pansclerotic morphea: clinical presentation in two adults. Maragh SH; Davis MD; Bruce AJ; Nelson AM J Am Acad Dermatol; 2005 Aug; 53(2 Suppl 1):S115-9. PubMed ID: 16021158 [TBL] [Abstract][Full Text] [Related]
19. Antibodies against antigens related to scleroderma in a cohort of patients with morphea. Arisi M; Cavazzana I; Cerutti ME; Ferrari F; Carabellese N; Rossi MT; Tincani A; Calzavara-Pinton P; Franceschini F G Ital Dermatol Venereol; 2018 Aug; 153(4):451-458. PubMed ID: 27706114 [TBL] [Abstract][Full Text] [Related]
20. Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies. Fett N Clin Dermatol; 2013; 31(4):432-437. PubMed ID: 23806160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]